ANX007

About Annexon

Annexon is developing a pipeline of novel therapeutics that inhibit the classical complement pathway by targeting C1q, aiming to address diseases driven by aberrant complement activation. Its lead programs are in clinical development for autoimmune, neurodegenerative, and ophthalmic conditions, with a focus on diseases where C1q-mediated inflammation and synaptic pruning are implicated. The company's strategy is to validate its platform through these clinical programs and expand into additional indications with high unmet medical need.

About Annexon

Annexon is developing a pipeline of novel therapeutics that inhibit the classical complement pathway by targeting C1q, aiming to address diseases driven by aberrant complement activation. Its lead programs are in clinical development for autoimmune, neurodegenerative, and ophthalmic conditions, with a focus on diseases where C1q-mediated inflammation and synaptic pruning are implicated. The company's strategy is to validate its platform through these clinical programs and expand into additional indications with high unmet medical need.

Therapeutic Areas